Regeneron’s adjusted profit rose 70% from a year earlier, sales rose 36%, and 3 key medicines reached record sales. Price pressure, copycat competition, and falling demand for older Eylea remain, but growth across key products and higher collaboration income point to a stronger outlook.
Growth came from several medicines, and higher income from the Sanofi collaboration added to sales. Price pressure, copycat competition, and falling demand for older Eylea are real risks. Still, sales and profit rose sharply, and Regeneron expects Eylea HD sales to grow further.
The article reports higher revenue for Regeneron from its Sanofi collaboration, but says nothing about Sanofi’s own sales or profit. It therefore does not change Sanofi’s outlook.
Follow Regeneron Pharmaceuticals Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for REGN